Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Non‐Invasive Prenatal Diagnosis of Spinal Muscular Atrophy Validated

By LabMedica International staff writers
Posted on 08 Oct 2019
The discovery of cell‐free DNA (cfDNA) in maternal plasma has enhanced the development of non‐invasive prenatal testing (NIPT). More...
Although NIPT for fetal aneuploidies has already been clinically applied, non‐invasive prenatal diagnosis for many single‐gene disorders remains on the developing stage.

Droplet digital PCR is a technology with high sensitivity, specificity, and accuracy to detect and analyze low-abundance nucleic acids. Its high resolution is guaranteed by millions of oil droplets generated per test. Utilizing digital PCR, the feasibility of non‐invasive prenatal diagnosis (NIPD) for fetal monogenic disorders has been proved in several studies analyzing cfDNA.

Medical Geneticists at the Central South University (Changsha, China) recruited pregnant women seeking Spinal Muscular Atrophy (SMA) prenatal diagnosis on 16 ~ 22 weeks of gestation for a study. All of the pregnancies had undergone non‐invasive prenatal screening for fetal aneuploidies by next‐generation sequencing (NGS).

The scientists extracted cell‐free DNA from maternal plasma using the QIAamp Circulating Nucleic Acid Kit and the concentrations of cfDNA samples were tested on Qubit. Amniotic fluid was obtained by amniocentesis, from which fetal genomic DNA was extracted by the phenol‐chloroform method. RainDrop droplet digital PCR was performed following standard protocols. SMN1/SMN2 copy numbers of all participants and fetuses were quantified by the multiplex ligation‐dependent probe amplification (MLPA) analysis using SALSA MLPA Kit.

The team reported that the concordance rate with the results of MLPA testing of amniocyte DNA was 94.12% in one test set and 90% in another set of participants. For all tests with a classifiable result, the percent of agreement with the results of MLPA testing of amniocyte DNA was up to 100% (25/25). The authors concluded that they had developed a direct, rapid, and low‐cost technique, which has a potential to be utilized for first‐trimester non‐invasive prenatal diagnosis and screening for spinal muscular atrophy with considerable reliability and feasibility. The study was published on September 25, 2019, in the Journal of Clinical Laboratory Analysis.

Related Links:
Central South University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Elevated creatinine levels do not necessarily indicate impaired kidney function: pre-treatment cystatin C measurement is key to assessment (Image Credit: Data panels adapted from Watanabe H, et al. Clin Pharmacol Ther (2026). All icons were obtained from bioicons.com and modified.)

Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury

Kidney function monitoring in breast cancer care often relies on serum creatinine, a routine blood marker used to estimate renal function. However, creatinine increases in patients receiving abemaciclib... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: The test uses serum or plasma from patients with suspected acute infection and symptoms lasting fewer than seven days and generates a score indicating the likelihood of bacterial infection. (Image Credit: Shutterstock)

Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections

Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.